Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Quorum Spinoff Deal Recognized as Finalist by 15th Annual M&A Advisor Awards

August 29, 2016

Nashville, Tenn., (August 29, 2016) - The M&A Advisor is pleased to announce the Finalists in the categories of M&A Deal of the Year, Restructuring Deal of the Year, Cross-Border Deal of the Year, Corporate/Strategic Acquisition of the Year, Deal Financing of the Year, Sector Deals of the Year, Firms of the Year, M&A Product/Service of the Year and M&A Professionals of the Year for the 15th Annual M&A Advisor Awards.

Bass, Berry & Sims was recognized as a Finalist as part of the deal team involving the "Spinoff of Quorum Health Corporation" in the following categories:

  • Healthcare and Life Sciences Deal of the Year (over $100MM)
  • Restructuring Deal of the Year (over $100MM)
  • Corporate and Strategic Acquisition Deal of the Year (over $500MM)
  • M&A Deal of the Year (over $1 billion - $5 billion)

The Finalists have been selected from the nominees in the first stage of evaluation, and the independent panel of judges will now focus their attention on the challenging task of selecting the ultimate award winners that will be announced at the Awards Gala on Wednesday, November 9 in New York - the premier celebration of the year for firms and professionals in the M&A industry. Held in conjunction with the Annual M&A Advisor Summit, the Gala will bring together the industry's leaders, vying for the 2016 Awards, to celebrate the Finalists and Winners.

The M&A Advisor
The M&A Advisor was founded in 1998 to offer insights and intelligence on mergers and acquisitions through the industry's leading publication. Today, the firm is recognized as the world's premier "think tank" and leadership organization for m&a, restructuring and financing professionals, providing a range of integrated services including: M&A Advisor Forums and Summits; M&A Advisor Market Intelligence; M&A.TV.; M&A Advisor Live; M&A Advisor Awards; and M&A Advisor Connects. For additional information about The M&A Advisor's leadership services visit www.maadvisor.com

About Bass, Berry & Sims PLC
With more than 260 attorneys representing numerous publicly traded companies and Fortune 500 businesses, Bass, Berry & Sims has been involved in some of the largest and most significant litigation matters and business transactions in the country. For more information, visit www.bassberry.com.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.